A quasquicentennial reflection on psoriasis

British Journal of Dermatology

Volumn 170, Issue 2, 2014, Pages 231-233

  Griffiths, C E M ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DERMATOLOGIC AGENTS; DERMATOLOGY; FORECASTING; HUMANS; PSORIASIS;

EID: 84894256806     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12834     Document Type: Editorial

References (21)

1. Valdimarsson H, Baker BS, Jõnsdõttir I, Fry L,. Psoriasis: a disease of abnormal keratinocyte proliferation induced by T lymphocytes. Immunol Today 1986; 7: 256-9.
2. Fry L,. Psoriasis. Br J Dermatol 1988; 119: 445-61.
3. Griffiths CEM, Powles AV, Leonard JN, et al,. Clearance of psoriasis with low dose cyclosporin. Br Med J 1986; 293: 731-2.
4. Gottlieb SL, Gilleaudeau P, Johnson R, et al,. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med 1995; 1: 442-7.
5. Leonardi C, Matheson R, Zachariae C, et al,. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med 2012; 366: 1190-9.
6. Papp KA, Leonardi C, Menter A, et al,. Brodalumab, an anti-interleukin-17 receptor antibody for psoriasis. N Engl J Med 2012; 366: 1181-9.
7. Papp KA, Langley RG, Sigurgeirsson B, et al,. Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study. Br J Dermatol 2013; 168: 412-21.
8. Papp KA, Menter A, Strober B, et al,. Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study. Br J Dermatol 2012; 167: 668-77.
9. Papp K, Cather JC, Rosoph L, et al,. Efficacy of apremilast in the treatment of moderate to severe psoriasis: a randomised controlled trial. Lancet 2012; 380: 738-46.
10. Identification and Management of Psoriasis Associated ComorbidiTy. Available at: www.impactpsoriasis.org.uk (last accessed 6 January 2014).
11. National Clinical Guideline Centre. Psoriasis: assessment and management of psoriasis. Available at: www.nice.org.uk/nicemedia/live/13938/61192/61192.pdf (last accessed 6 January 2014).
12. Gelfand JM, Neimann AL, Shin DB, et al,. Risk of myocardial infarction in patients with psoriasis. JAMA 2006; 296: 1735-41.
13. Dowlatshahi EA, Kavousi M, Nijsten T, et al,. Psoriasis is not associated with atherosclerosis and incident cardiovascular events: the Rotterdam study. J Invest Dermatol 2013; 133: 2347-54.
14. Setty AR, Curhan G, Choi HK,. Obesity, weight circumference, weight change and the risk of psoriasis in women: Nurses' Health Study II. Arch Intern Med 2007; 167: 1670-5.
15. Marrakchi S, Guigue P, Renshaw BR, et al,. Interlekin-36-receptor antagonist deficiency and generalized pustular psoriasis. N Engl J Med 2011; 365: 620-8.
16. Allen MH, Ameen H, Veal C, et al,. The major psoriasis susceptibility locus PSORS1 is not a risk factor for late-onset psoriasis. J Invest Dermatol 2005; 124: 103-6.
17. Hébert HL, Bowes J, Smith RL, et al,. Polymorphisms in IL-1B distinguish between psoriasis of early and late onset. J Invest Dermatol 2013; [Epub ahead of print].
18. Shaw FL, Cumberbatch M, Kleyn CE, et al,. Langerhans cell mobilization distinguishes between early-onset and late-onset psoriasis. J Invest Dermatol 2010; 130: 1940-2.
19. Talamonti M, Botti E, Galluzzo M, et al,. Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab. Br J Dermatol 2013; 169: 458-63.
20. Burden AD, Warren RB, Kleyn CE, et al,. The British Association of Dermatologists' Biologic Interventions Register (BADBIR): design, methodology and objectives. Br J Dermatol 2012; 166: 545-54.
21. Psoriasis Stratification to Optimise Relevant Therapy. Available at: www.psort.org.uk (last accessed 6 January 2014).